Drug Trial Radar · NCT07799688
A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 11, 2026
Primary completion
Oct 15, 2028
Study completion Oct 15, 2028
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants. Cohort 1 includes subjects who completed parent study HRS-7249-201 within 24 weeks; Cohort 2 newly recruited patients with fasting triglyceride (TG) ≥2.3 mmol/L aged 18-79 years. All participants receive subcutaneous HRS-7249 for a 48-week treatment period followed by a 24-week safety follow-up phase, with two dosing regimens. The primary objective is to assess long-term safety and tolerability of repeated HRS-7249 administration. Secondary objectives include evaluating sustained lipid-lowering effects on TG, APOC3 and other lipid profiles, impacts on glycometabolism, incidence of acute pancreatitis and major adverse cardiovascular events (MACE), long-term pharmacokinetic/pharmacodynamic (PK/PD) profiles, and anti-drug antibody (ADA) dynamics. All safety assessments including vital signs, physical examinations, laboratory tests, 12-lead ECG, injection site reactions and adverse events will be collected throughout the study. Lipid parameters, HbA1c, pancreatitis and cardiovascular events will be monitored to characterize the clinical benefit-risk profile of long-term HRS-7249 therapy in hypertriglyceridemia patients. A total of at least 400 subjects will be enrolled nationwide in China.
Conditions
- Hyperlipidemia
Interventions
HRS-7249 InjectionDrug
Dosing level: Low dose
HRS-7249 InjectionDrug
Dosing level: High dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Injection site reactionsTime frame: 48 weeks
- All adverse events (AEs)Time frame: 72 weeks
- Respiratory rateTime frame: 72 weeks
- Pulse rateTime frame: 72 weeks
- Systolic and diastolic blood pressureTime frame: 72 weeks
- Body temperatureTime frame: 72 weeks
- Complete Blood CountTime frame: 72 weeks
- Blood chemistryTime frame: 72 weeks
- High-sensitivity C-reactive protein (hs-CRP)Time frame: 72 weeks;
- Heart rateTime frame: 72 weeks;
- PR intervalTime frame: 72 weeks
- QRS durationTime frame: 72 weeks
- QT intervalTime frame: 72 weeks
- QTc intervalTime frame: 72 weeks
- UrinalysisTime frame: 72 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University (Qianfo Shan Hospital of shandong province).
Jinan, Shandong, China · Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.